N-[5-(2-Furanyl)-1,3,4-oxadiazol-2-yl]-N′-(2-pyridinylmethyl)-urea

NK 252 is a Nrf2 activator that interacts directly with the domain containing the Nrf2-binding site of Keap1. At 1.36 μM, it is reported to activate the NQO1-antioxidant response element in a luciferase reporter gene assay two-fold above background. NK 252 has been shown to downregulate the expression of fibrogenic genes, producing antifibrotic effects in a rat model of non-alcoholic steatohepatitis.

NK 252 is a Nrf2-activator. It exhibits a greater Nrf2-activating potential than OPZ.

Store at +4°C

[1]. shimozono r, asaoka y, yoshizawa y, et al. nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. mol pharmacol. 2013 jul;84(1):62-70.
[2]. kiue a, sano t, naito a, et al. reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse p388 leukemia in vivo and in vitro. jpn j cancer res. 1990 oct;81(10):1057-64.